For example, in the treatment of breast cancer, women with ultra-low expression of HER2 have been shown to benefit from trastuzumab deruxtecan treatment.14 Antibody-drug conjugates have changed the treatment paradigms for several types of cancer. This evidence concerns the gene ERBB2 and breast cancer.